Stocks making the biggest moves after hours: Avis, Stryker and more

Market Insider

In this article

A customer waits for his car at the garage of Avis Budget Group at the San Francisco airport.
David Paul Morris | Bloomberg | Getty Images

Check out the companies making headlines in after-hours trading.

Avis Budget Group – Shares of the budget care rental company jumped 2% following its quarterly results. Avis reported adjusted per-share earnings of $21.70, compared to expectations of $14.64 per share, according to Refinitiv.

Stryker – The medical technology company fell 5.5% after it reported a miss on the top line in its latest quarterly results. Stryker posted adjusted earnings per share of $2.12, compared to estimates of $2.23, according to Refinitiv. The company narrowly beat expectations on revenue.

Hologic – Shares of the medical supplier added 7.5% as it beat expectations of analysts’ expectations on top and bottom lines for the latest quarter, according to Street Account. For the fiscal year ending September 2023, the company expects earnings per share between $3.30 and $3.60 compared to FactSet’s expectation of $3.43, while revenue is expected by the company between $3.7 billion and $3.9 billion against the anticipated $3.81 billion.

Goodyear Tire & Rubber Company – Shares of the tire company tumbled more than 8%. Goodyear posted quarterly earnings per share of 40 cents on revenue of $5.31 billion. Analysts expected per-share earnings of 55 cents on revenue of $5.36 billion, according to Street Account.

IDEXX Laboratories – The science company with a focus on animals and water added 2.8% in post-market trading as investors looked to earnings coming Tuesday ahead of the market’s open.

Articles You May Like

Tech Wreck Trio: 3 Stocks to Eject Before They Short-Circuit Your Portfolio
7 Dividend Stocks to Buy as the Fed Mulls Rate Cuts
Leave Tesla Stock at the Charging Station for Now
Hidden Tech Titans: 3 Stocks Ready to Rocket Past Market Expectations by 2027
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade